What are GLP-1 medications?
GLP-1 receptor agonists are a class of medications originally developed for type 2 diabetes that have shown remarkable results for weight management. They work by:
- Reducing appetite: GLP-1s act on the brain's appetite centres, helping you feel full sooner and reducing cravings
- Slowing gastric emptying: Food stays in your stomach longer, keeping you satisfied between meals
- Improving metabolic health: Beyond weight loss, GLP-1s can improve blood sugar, cholesterol, and cardiovascular risk markers
Clinical trials have demonstrated average weight loss of 15-20% of body weight with newer GLP-1 medications like semaglutide (Wegovy) and tirzepatide (Mounjaro).
Available GLP-1 medications in Canada
Several GLP-1 medications are approved by Health Canada for weight management:
- Ozempic (semaglutide): Originally for diabetes, widely prescribed off-label for weight loss. Weekly injection.
- Wegovy (semaglutide): The same active ingredient as Ozempic, specifically approved for chronic weight management at a higher dose. Weekly injection.
- Mounjaro (tirzepatide): A dual GIP/GLP-1 receptor agonist showing the highest weight loss results in clinical trials. Weekly injection.
- Saxenda (liraglutide): An older GLP-1 option, daily injection. Still effective for many patients.
Your nurse practitioner will recommend the best option based on your health profile, goals, and medication availability.
Who qualifies for GLP-1 treatment?
GLP-1 medications for weight management are generally appropriate for adults who meet one of these criteria:
- BMI of 30 or higher (obesity)
- BMI of 27 or higher with at least one weight-related health condition (high blood pressure, type 2 diabetes, high cholesterol, sleep apnea)
Your nurse practitioner will also consider:
- Your medical history and current medications
- Whether you have tried lifestyle changes (diet, exercise) previously
- Any contraindications (personal or family history of medullary thyroid cancer, pancreatitis history, etc.)
How the online consultation works
Getting started with GLP-1 treatment through MedRelay is straightforward:
- Complete the questionnaire (5 minutes): Answer questions about your weight history, health conditions, current medications, and goals.
- NP review (within 24 hours): A licensed nurse practitioner reviews your case asynchronously. For straightforward cases, no video call is needed.
- Treatment plan: If you qualify, your NP creates a personalized plan including medication selection, dosing schedule, and lifestyle recommendations.
- Prescription to your pharmacy: Your prescription is sent electronically to the pharmacy of your choice.
The entire process can be completed without leaving your home. If your NP has questions or your case requires deeper discussion, they may request a brief video consultation at no extra charge.
Cost and what is included
A weight loss consultation through MedRelay costs $99. This includes:
- Comprehensive health questionnaire review
- NP assessment and treatment plan
- Prescription (if clinically appropriate)
- Dosing guidance and titration schedule
- One follow-up message for questions
Medication costs are separate. GLP-1 medications can range from $300 to $1,000+ per month depending on the specific medication and dosage. Many private insurance plans cover some or all of this cost. Your pharmacist can help you check coverage.
Frequently asked questions
Do I need blood work before starting?
Your NP may recommend baseline blood work (A1C, kidney function, thyroid) depending on your health history. This can be done at any local lab.
How quickly will I see results?
Most patients notice reduced appetite within the first week. Significant weight loss typically becomes visible within 4-8 weeks as the dose is gradually increased.
Are there side effects?
Common side effects include nausea, which usually improves over time. Gradual dose titration minimizes this. Your NP will provide a complete overview of what to expect.
Can a nurse practitioner prescribe Ozempic?
Yes. Licensed nurse practitioners in Ontario, Alberta, BC, Saskatchewan, and Nova Scotia have full prescriptive authority and can prescribe GLP-1 medications.